-
1
-
-
77649234756
-
How to improve R&D productivity: The pharmaceutical industry's grand challenge
-
Paul, S.M. et al. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010
-
(2010)
Nat. Rev. Drug Discov
, vol.9
, pp. 203-214
-
-
Paul, S.M.1
-
2
-
-
79955601786
-
Trial watch: Phase II failures: 2008-2010
-
Arrowsmith, J. Trial watch: Phase II failures: 2008-2010. Nat. Rev. Drug Discov. 10, 328- 329 (2011
-
(2011)
Nat. Rev. Drug Discov
, vol.10
, pp. 328-329
-
-
Arrowsmith, J.1
-
3
-
-
79959736059
-
Market withdrawal of new molecular entities approved in the United States from 1980 to 2009
-
Qureshi, Z.P., Seoane-Vazquez, E., Rodriguez-Monguio, R., Stevenson, K.B. & Szeinbach, S.L. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol. Drug Saf. 20, 772-777 (2011
-
(2011)
Pharmacoepidemiol. Drug Saf
, vol.20
, pp. 772-777
-
-
Qureshi, Z.P.1
Seoane-Vazquez, E.2
Rodriguez-Monguio, R.3
Stevenson, K.B.4
Szeinbach, S.L.5
-
4
-
-
70449528780
-
In silico toxicology for the pharmaceutical sciences
-
Valerio, L.G. Jr. In silico toxicology for the pharmaceutical sciences. Toxicol. Appl. Pharmacol. 241, 356-370 (2009
-
(2009)
Toxicol. Appl. Pharmacol
, vol.241
, pp. 356-370
-
-
Valerio Jr., L.G.1
-
5
-
-
84862523209
-
Web tools for predictive toxicology model building
-
Jeliazkova, N. Web tools for predictive toxicology model building. Expert Opin. Drug Metab. Toxicol. 8, 791-801 (2012
-
(2012)
Expert Opin. Drug Metab. Toxicol
, vol.8
, pp. 791-801
-
-
Jeliazkova, N.1
-
6
-
-
79955745792
-
Impact of computational structure-based predictive toxicology in drug discovery
-
Mohan, C.G. Impact of computational structure-based predictive toxicology in drug discovery. Comb. Chem. High Throughput Screen. 14, 417-426 (2011
-
(2011)
Comb. Chem. High Throughput Screen
, vol.14
, pp. 417-426
-
-
Mohan, C.G.1
-
7
-
-
84865271285
-
Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results
-
Yoon, M., Campbell, J.L., Andersen, M.E. & Clewell, H.J. Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Crit. Rev. Toxicol. 42, 633-652 (2012
-
(2012)
Crit. Rev. Toxicol
, vol.42
, pp. 633-652
-
-
Yoon, M.1
Campbell, J.L.2
Andersen, M.E.3
Clewell, H.J.4
-
8
-
-
49949104757
-
SLCO1B1 variants and statin-induced myopathy-A genomewide study
-
Link, E. et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359, 789-799 (2008
-
(2008)
N. Engl. J. Med
, vol.359
, pp. 789-799
-
-
Link, E.1
-
9
-
-
0014858473
-
Generalized solution to linear, to compartment, open model for drug distribution
-
Bischoff, K.B. & Dedrick, R.L. Generalized solution to linear, to compartment, open model for drug distribution. J. Theor. Biol. 29, 63-68 (1970
-
(1970)
J. Theor. Biol
, vol.29
, pp. 63-68
-
-
Bischoff, K.B.1
Dedrick, R.L.2
-
10
-
-
58849107587
-
Meeting report: Moving upstream-evaluating adverse upstream end points for improved risk assessment and decision-making
-
Woodruff, T.J. et al. Meeting report: moving upstream-evaluating adverse upstream end points for improved risk assessment and decision-making. Environ. Health Perspect. 116, 1568-1575 (2008
-
(2008)
Environ. Health Perspect
, vol.116
, pp. 1568-1575
-
-
Woodruff, T.J.1
-
11
-
-
78649736009
-
PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals
-
Bois, F.Y., Jamei, M. & Clewell, H.J. PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology 278, 256-267 (2010
-
(2010)
Toxicology
, vol.278
, pp. 256-267
-
-
Bois, F.Y.1
Jamei, M.2
Clewell, H.J.3
-
12
-
-
41949099850
-
Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: The first steps
-
Loizou, G. et al. Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: The first steps. Regul. Toxicol. Pharmacol. 50, 400-411 (2008
-
(2008)
Regul. Toxicol. Pharmacol
, vol.50
, pp. 400-411
-
-
Loizou, G.1
-
13
-
-
33748338819
-
From physicochemistry to absorption and distribution: Predictive mechanistic modelling and computational tools
-
Willmann, S., Lippert, J. & Schmitt, W. From physicochemistry to absorption and distribution: Predictive mechanistic modelling and computational tools. Expert Opin. Drug Metab. Toxicol. 1, 159-168 (2005
-
(2005)
Expert Opin. Drug Metab. Toxicol
, vol.1
, pp. 159-168
-
-
Willmann, S.1
Lippert, J.2
Schmitt, W.3
-
14
-
-
70450240777
-
Risk to the breast-fed neonate from codeine treatment to the mother: A quantitative mechanistic modeling study
-
Willmann, S., Edginton, A.N., Coboeken, K., Ahr, G. & Lippert, J. Risk to the breast-fed neonate from codeine treatment to the mother: A quantitative mechanistic modeling study. Clin. Pharmacol. Ther. 86, 634-643 (2009
-
(2009)
Clin. Pharmacol. Ther
, vol.86
, pp. 634-643
-
-
Willmann, S.1
Edginton, A.N.2
Coboeken, K.3
Ahr, G.4
Lippert, J.5
-
15
-
-
34447330544
-
Whole-body physiologically based pharmacokinetic models
-
Nestorov, I. Whole-body physiologically based pharmacokinetic models. Expert Opin. Drug Metab. Toxicol. 3, 235-249 (2007
-
(2007)
Expert Opin. Drug Metab. Toxicol
, vol.3
, pp. 235-249
-
-
Nestorov, I.1
-
16
-
-
0036075799
-
Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition
-
Poulin, P. & Theil, F.P. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J. Pharm. Sci. 91, 1358-1370 (2002
-
(2002)
J. Pharm. Sci
, vol.91
, pp. 1358-1370
-
-
Poulin, P.1
Theil, F.P.2
-
17
-
-
0028650743
-
Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125
-
Kawai, R., Lemaire, M., Steimer, J.L., Bruelisauer, A., Niederberger, W. & Rowland, M. Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J. Pharmacokinet. Biopharm. 22, 327-365 (1994
-
(1994)
J. Pharmacokinet. Biopharm
, vol.22
, pp. 327-365
-
-
Kawai, R.1
Lemaire, M.2
Steimer, J.L.3
Bruelisauer, A.4
Niederberger, W.5
Rowland, M.6
-
18
-
-
0029549676
-
Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development
-
Charnick, S.B., Kawai, R., Nedelman, J.R., Lemaire, M., Niederberger, W. & Sato, H. Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development. J. Pharmacokinet. Biopharm. 23, 217-229 (1995
-
(1995)
J. Pharmacokinet. Biopharm
, vol.23
, pp. 217-229
-
-
Charnick, S.B.1
Kawai, R.2
Nedelman, J.R.3
Lemaire, M.4
Niederberger, W.5
Sato, H.6
-
19
-
-
13244280971
-
PK-Sim: A Physiologically Based Pharmacokinetic "whole-body" model
-
Willmann, S. et al. PK-Sim: A physiologically based pharmacokinetic "whole-body" model. Biosilico 1, 121-124 (2003
-
(2003)
Biosilico
, vol.1
, pp. 121-124
-
-
Willmann, S.1
-
20
-
-
3242778534
-
A physiological model for the estimation of the fraction dose absorbed in humans
-
Willmann, S., Schmitt, W., Keldenich, J., Lippert, J. & Dressman, J.B. A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. 47, 4022-4031 (2004
-
(2004)
J. Med. Chem
, vol.47
, pp. 4022-4031
-
-
Willmann, S.1
Schmitt, W.2
Keldenich, J.3
Lippert, J.4
Dressman, J.B.5
-
21
-
-
84859883744
-
Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling
-
Meyer, M., Schneckener, S., Ludewig, B., Kuepfer, L. & Lippert, J. Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. Drug Metab. Dispos. 40, 892-901 (2012
-
(2012)
Drug Metab. Dispos
, vol.40
, pp. 892-901
-
-
Meyer, M.1
Schneckener, S.2
Ludewig, B.3
Kuepfer, L.4
Lippert, J.5
-
22
-
-
9444256954
-
Toxicogenomics and systems toxicology: Aims and prospects
-
Waters, M.D. & Fostel, J.M. Toxicogenomics and systems toxicology: Aims and prospects. Nat. Rev. Genet. 5, 936-948 (2004
-
(2004)
Nat. Rev. Genet
, vol.5
, pp. 936-948
-
-
Waters, M.D.1
Fostel, J.M.2
-
23
-
-
76949094840
-
Risk factors and drug interactions predisposing to statin-induced myopathy: Implications for risk assessment, prevention and treatment
-
Chatzizisis, Y.S., Koskinas, K.C., Misirli, G., Vaklavas, C., Hatzitolios, A. & Giannoglou, G.D. Risk factors and drug interactions predisposing to statin-induced myopathy: Implications for risk assessment, prevention and treatment. Drug Saf. 33, 171-187 (2010
-
(2010)
Drug Saf
, vol.33
, pp. 171-187
-
-
Chatzizisis, Y.S.1
Koskinas, K.C.2
Misirli, G.3
Vaklavas, C.4
Hatzitolios, A.5
Giannoglou, G.D.6
-
24
-
-
70349739250
-
The SLCO1B1. 5 genetic variant is associated with statin-induced side effects
-
Voora, D. et al. The SLCO1B1. 5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54, 1609-1616 (2009
-
(2009)
J. Am. Coll. Cardiol
, vol.54
, pp. 1609-1616
-
-
Voora, D.1
-
25
-
-
79953901458
-
Organic anion transporting polypeptide 1B1: A genetically polymorphic transporter of major importance for hepatic drug uptake
-
Niemi, M., Pasanen, M.K. & Neuvonen, P.J. Organic anion transporting polypeptide 1B1: A genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev. 63, 157-181 (2011
-
(2011)
Pharmacol. Rev
, vol.63
, pp. 157-181
-
-
Niemi, M.1
Pasanen, M.K.2
Neuvonen, P.J.3
-
26
-
-
72249115539
-
Does simvastatin cause more myotoxicity compared with other statins?
-
Backes, J.M., Howard, P.A., Ruisinger, J.F. & Moriarty, P.M. Does simvastatin cause more myotoxicity compared with other statins? Ann. Pharmacother. 43, 2012-2020 (2009
-
(2009)
Ann. Pharmacother
, vol.43
, pp. 2012-2020
-
-
Backes, J.M.1
Howard, P.A.2
Ruisinger, J.F.3
Moriarty, P.M.4
-
27
-
-
33749049136
-
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
-
Niemi, M., Pasanen, M.K. & Neuvonen, P.J. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 80, 356-366 (2006
-
(2006)
Clin. Pharmacol. Ther
, vol.80
, pp. 356-366
-
-
Niemi, M.1
Pasanen, M.K.2
Neuvonen, P.J.3
-
28
-
-
33751096467
-
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
-
Pasanen, M.K., Neuvonen, M., Neuvonen, P.J. & Niemi, M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16, 873-879 (2006
-
(2006)
Pharmacogenet. Genomics
, vol.16
, pp. 873-879
-
-
Pasanen, M.K.1
Neuvonen, M.2
Neuvonen, P.J.3
Niemi, M.4
-
29
-
-
0141569210
-
Clinical pharmacokinetics of statins
-
García, M.J., Reinoso, R.F., Sánchez Navarro, A. & Prous, J.R. Clinical pharmacokinetics of statins. Methods Find. Exp. Clin. Pharmacol. 25, 457-481 (2003
-
(2003)
Methods Find. Exp. Clin. Pharmacol
, vol.25
, pp. 457-481
-
-
García, M.J.1
Reinoso, R.F.2
Sánchez Navarro, A.3
Prous, J.R.4
-
30
-
-
0034495168
-
Clinical pharmacokinetics of pravastatin: Mechanisms of pharmacokinetic events
-
Hatanaka, T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin. Pharmacokinet. 39, 397-412 (2000
-
(2000)
Clin. Pharmacokinet
, vol.39
, pp. 397-412
-
-
Hatanaka, T.1
-
31
-
-
33846034416
-
Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans
-
Kivistö, K.T. & Niemi, M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res. 24, 239-247 (2007
-
(2007)
Pharm. Res
, vol.24
, pp. 239-247
-
-
Kivistö, K.T.1
Niemi, M.2
-
32
-
-
2042469487
-
Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics
-
Mwinyi, J., Johne, A., Bauer, S., Roots, I. & Gerloff, T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 75, 415-421 (2004
-
(2004)
Clin. Pharmacol. Ther
, vol.75
, pp. 415-421
-
-
Mwinyi, J.1
Johne, A.2
Bauer, S.3
Roots, I.4
Gerloff, T.5
-
33
-
-
0025355830
-
Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects
-
Singhvi, S.M., Pan, H.Y., Morrison, R.A. & Willard, D.A. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 29, 239-243 (1990
-
(1990)
Br. J. Clin. Pharmacol
, vol.29
, pp. 239-243
-
-
Singhvi, S.M.1
Pan, H.Y.2
Morrison, R.A.3
Willard, D.A.4
-
34
-
-
0025771262
-
Biotransformation of pravastatin sodium in humans
-
Everett, D.W., Chando, T.J., Didonato, G.C., Singhvi, S.M., Pan, H.Y. & Weinstein, S.H. Biotransformation of pravastatin sodium in humans. Drug Metab. Dispos. 19, 740-748 (1991
-
(1991)
Drug Metab. Dispos
, vol.19
, pp. 740-748
-
-
Everett, D.W.1
Chando, T.J.2
Didonato, G.C.3
Singhvi, S.M.4
Pan, H.Y.5
Weinstein, S.H.6
-
35
-
-
0025077819
-
Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia
-
Todd, P.A. & Goa, K.L. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 40, 583-607 (1990
-
(1990)
Drugs
, vol.40
, pp. 583-607
-
-
Todd, P.A.1
Goa, K.L.2
-
36
-
-
72849141790
-
Transporter pharmacogenetics and statin toxicity
-
Niemi, M. Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther. 87, 130-133 (2010
-
(2010)
Clin. Pharmacol. Ther
, vol.87
, pp. 130-133
-
-
Niemi, M.1
-
37
-
-
34948840834
-
Ensemble modeling for analysis of cell signaling dynamics
-
Kuepfer, L., Peter, M., Sauer, U. & Stelling, J. Ensemble modeling for analysis of cell signaling dynamics. Nat. Biotechnol. 25, 1001-1006 (2007
-
(2007)
Nat. Biotechnol
, vol.25
, pp. 1001-1006
-
-
Kuepfer, L.1
Peter, M.2
Sauer, U.3
Stelling, J.4
-
38
-
-
80054718671
-
A computational systems biology software platform for multiscale modeling and simulation: Integrating whole-body physiology, disease biology, and molecular reaction networks
-
Eissing, T. et al. A computational systems biology software platform for multiscale modeling and simulation: Integrating whole-body physiology, disease biology, and molecular reaction networks. Front. Physiol. 2, 4 (2011
-
(2011)
Front. Physiol
, vol.2
, Issue.4
-
-
Eissing, T.1
-
39
-
-
34249905607
-
Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs
-
Willmann, S. et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J. Pharmacokinet. Pharmacodyn. 34, 401-431 (2007
-
(2007)
J. Pharmacokinet. Pharmacodyn
, vol.34
, pp. 401-431
-
-
Willmann, S.1
-
40
-
-
41749102617
-
Association between risk of myopathy and cholesterol-lowering effect: A comparison of all statins
-
Kobayashi, M. et al. Association between risk of myopathy and cholesterol-lowering effect: A comparison of all statins. Life Sci. 82, 969-975 (2008
-
(2008)
Life Sci
, vol.82
, pp. 969-975
-
-
Kobayashi, M.1
-
41
-
-
0037031061
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebocontrolled trial
-
Heart Protection Study Collaborative Group
-
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebocontrolled trial. Lancet 360, 7-22, (2002
-
(2002)
Lancet
, vol.360
, pp. 7-22
-
-
-
42
-
-
33745031039
-
Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population
-
Pasanen, M.K., Backman, J.T., Neuvonen, P.J. & Niemi, M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur. J. Clin. Pharmacol. 62, 409-415 (2006
-
(2006)
Eur. J. Clin. Pharmacol
, vol.62
, pp. 409-415
-
-
Pasanen, M.K.1
Backman, J.T.2
Neuvonen, P.J.3
Niemi, M.4
-
43
-
-
84857610609
-
Pharmacogenomics of codeine, morphine, and morphine- 6-glucuronide: Model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition
-
Eissing, T., Lippert, J. & Willmann, S. Pharmacogenomics of codeine, morphine, and morphine- 6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition. Mol. Diagn. Ther. 16, 43-53 (2012
-
(2012)
Mol. Diagn. Ther
, vol.16
, pp. 43-53
-
-
Eissing, T.1
Lippert, J.2
Willmann, S.3
-
44
-
-
83755196415
-
Statin-associated muscular and renal adverse events: Data mining of the public version of the FDA adverse event reporting system
-
Sakaeda, T., Kadoyama, K. & Okuno, Y. Statin-associated muscular and renal adverse events: Data mining of the public version of the FDA adverse event reporting system. PLoS ONE 6, e28124 (2011
-
(2011)
PLoS ONE
, vol.6
-
-
Sakaeda, T.1
Kadoyama, K.2
Okuno, Y.3
-
45
-
-
0036144815
-
Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism- based prediction of volume of distribution
-
Poulin, P. & Theil, F.P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism- based prediction of volume of distribution. J. Pharm. Sci. 91, 129-156 (2002
-
(2002)
J. Pharm. Sci
, vol.91
, pp. 129-156
-
-
Poulin, P.1
Theil, F.P.2
-
46
-
-
21344469211
-
Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases
-
Rodgers, T., Leahy, D. & Rowland, M. Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases. J. Pharm. Sci. 94, 1259- 1276 (2005
-
(2005)
J. Pharm. Sci
, vol.94
, pp. 1259-1276
-
-
Rodgers, T.1
Leahy, D.2
Rowland, M.3
-
47
-
-
0034283671
-
Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: Involvement of an inhibitory G protein
-
Sadeghi, M.M., Collinge, M., Pardi, R. & Bender, J.R. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: Involvement of an inhibitory G protein. J. Immunol. 165, 2712-2718 (2000
-
(2000)
J. Immunol
, vol.165
, pp. 2712-2718
-
-
Sadeghi, M.M.1
Collinge, M.2
Pardi, R.3
Bender, J.R.4
-
48
-
-
22544454498
-
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1.*5, SLCO1B1.*15 and SLCO1B1.*15+C1007G, by using transient expression systems of HeLa and HEK293 cells
-
Kameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M. & Chiba, K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1.*5, SLCO1B1.*15 and SLCO1B1.*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 15, 513-522 (2005
-
(2005)
Pharmacogenet. Genomics
, vol.15
, pp. 513-522
-
-
Kameyama, Y.1
Yamashita, K.2
Kobayashi, K.3
Hosokawa, M.4
Chiba, K.5
|